menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mentis Cura","sponsor":"Landspitali University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Undisclosed","graph3":"Mentis Cura","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mentis Cura \/ Landspitali University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Mentis Cura \/ Landspitali University Hospital"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medical Corps, Israel Defense Force \/ Undisclosed"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medical Corps, Israel Defense Force \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Yale University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Taub Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Taub Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Taub Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taub Group \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Repurposed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Repurposed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Repurposed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repurposed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repurposed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Repurposed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals for Scopolamine

    Menu

    Scopolamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yale University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Yale University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2023

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CMC Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CMC Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate,Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : US Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical...

                            Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 06, 2022

                            Lead Product(s) : Atropine Sulfate,Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : US Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Motion Sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2020

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Motion Sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2019

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Prevention and Treatment of Nausea Associated With Motion Sickness

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Motion Sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 14, 2019

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Repurposed Therapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Scopolamine in Healthy Volunteers

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 14, 2019

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Taub Group

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Taub Group

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depression.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 29, 2017

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medical Corps, Israel Defense Force

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Medical Corps, Israel Defense Force

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Motion Sickness Medications and Vestibular Time Constant

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2017

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Takeda Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TAK-071 Scopolamine-Induced Cognitive Impairment Study

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 28, 2016

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery...

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Motion Sickness.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 20, 2016

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth